Beamr video compression achieves up to 50% improvement for AVs
Investing.com -- The U.S. Food and Drug Administration approved Gilead Sciences (NASDAQ:GILD)’ lenacapavir on Wednesday, a new HIV prevention treatment administered as an injection twice per year.
The drug, which will be marketed under the brand name Yeztugo, is approved for use in both adults and adolescents seeking pre-exposure prophylaxis against HIV infection.
Gilead’s lenacapavir represents a significant addition to HIV prevention options, offering patients an alternative to daily oral medications with its twice-yearly dosing schedule.
The FDA’s decision adds a new tool to the arsenal of HIV prevention methods, potentially increasing accessibility and adherence for those at risk of HIV infection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.